Display options
Cite
Takase B, Hattori H, Tanaka Y, et al. Pitavastatin subacutely improves endothelial function and reduces inflammatory cytokines and chemokines in patients with hypercholesterolaemia. Heart Asia. 2013;5(1):204-9doi: 10.1136/heartasia-2013-010368.
Takase, B., Hattori, H., Tanaka, Y., Nagata, M., & Ishihara, M. (2013). Pitavastatin subacutely improves endothelial function and reduces inflammatory cytokines and chemokines in patients with hypercholesterolaemia. Heart Asia, 5(1), 204-9. https://doi.org/10.1136/heartasia-2013-010368
Takase, Bonpei, et al. "Pitavastatin subacutely improves endothelial function and reduces inflammatory cytokines and chemokines in patients with hypercholesterolaemia." Heart Asia vol. 5,1 (2013): 204-9. doi: https://doi.org/10.1136/heartasia-2013-010368
Takase B, Hattori H, Tanaka Y, Nagata M, Ishihara M. Pitavastatin subacutely improves endothelial function and reduces inflammatory cytokines and chemokines in patients with hypercholesterolaemia. Heart Asia. 2013 Sep 13;5(1):204-9. doi: 10.1136/heartasia-2013-010368. eCollection 2013. PMID: 27326130; PMCID: PMC4832709.
Copy Download .nbib Format: NLM
Share it on

Heart Asia. 2013 Sep 13;5(1):204-9. doi: 10.1136/heartasia-2013-010368. eCollection 2013.

Pitavastatin subacutely improves endothelial function and reduces inflammatory cytokines and chemokines in patients with hypercholesterolaemia.

Heart Asia

Bonpei Takase, Hidemi Hattori, Yoshihiro Tanaka, Masayoshi Nagata, Masayuki Ishihara

Affiliations

  1. Department of Intensive Care Medicine , National Defense Medical College , Saitama , Japan.
  2. Division of Biomedical Engineering , National Defense Medical College Research Institute , Saitama , Japan.
  3. Department of Internal Medicine , Iruma Heart Hospital , Saitama , Japan.

PMID: 27326130 PMCID: PMC4832709 DOI: 10.1136/heartasia-2013-010368

Abstract

BACKGROUND: Pitavastatin is a statin with strong pleiotropic effects, but the effects of pitavastatin on endothelial cell function (ECF) and both inflammatory cytokines and chemokines have not been fully investigated.

MATERIAL AND METHODS: We simultaneously measured brachial artery (BA) flow-mediated vasodilatation (FMD) and nitroglycerin-mediated vasodilatation (NMD), as well as plasma biomarkers of inflammatory cytokines and chemokines, in patients with hypercholesterolaemia and other atherosclerotic risk factors who were treated with pitavastatin. Sixty-five hypercholesterolaemic patients (age, 66±11 years) with conventional coronary risk factors were enrolled. BA FMD, BA NMD and serum biomarkers (tumour necrosis factor, interleukin (IL)-6, IL-10, monocyte chemoattractant protein-1, IL-8, P-selectin, E-selectin, soluble intercellular cell adhesion molecule-1 (s-ICAM1)) were measured before and after 4 weeks of treatment with pitavastatin (2 mg/day).

RESULTS: Pitavastatin treatment resulted in an increase from baseline to post-treatment in FMD (3.22±1.72 vs 3.97±2.18%, p<0.05) but not in NMD. Furthermore, pitavastatin treatment led to a decrease from baseline to post-treatment in E-selectin (51±27 vs 46±29 pg/mL, p<0.05) and s-ICAM1 (276±86 vs 258±91 pg/mL, p<0.05). Changes in FMD in response to pitavastatin treatment did not correlate with those of E-selectin or s-ICAM1.

CONCLUSIONS: Pitavastatin treatment resulted in a subacute improvement in ECF and a decrease in chemokine levels. These results suggest that pitavastatin might improve long-term outcomes in patients with atherosclerotic disorders.

References

  1. Am J Cardiol. 1998 Dec 15;82(12):1535-9, A7-8 - PubMed
  2. Circ J. 2004 Nov;68(11):1067-75 - PubMed
  3. Hypertens Res. 2008 Nov;31(11):2019-25 - PubMed
  4. Free Radic Biol Med. 2005 Aug 15;39(4):444-52 - PubMed
  5. Yakugaku Zasshi. 2004 Mar;124(3):121-6 - PubMed
  6. Am J Hypertens. 2009 Feb;22(2):176-82 - PubMed
  7. J Atheroscler Thromb. 2002;9(4):178-83 - PubMed
  8. Circulation. 2003 Jul 29;108(4):426-31 - PubMed
  9. Circ J. 2009 Aug;73(8):1523-30 - PubMed
  10. Hypertension. 2010 Apr;55(4):918-23 - PubMed
  11. Br J Pharmacol. 2010 Apr;159(7):1418-28 - PubMed
  12. J Vasc Res. 2006;43(2):131-8 - PubMed
  13. Curr Eye Res. 2009 Jan;34(1):10-7 - PubMed
  14. Br J Clin Pharmacol. 2012 Apr;73(4):518-35 - PubMed
  15. Circ J. 2010 Jan;74(1):195-202 - PubMed
  16. Heart Vessels. 2011 Jul;26(4):428-34 - PubMed
  17. Metabolism. 2008 May;57(5):691-7 - PubMed
  18. Circulation. 1997 Sep 2;96(5):1381-5 - PubMed
  19. Int J Cardiol. 2006 Nov 18;113(3):305-10 - PubMed
  20. J Cardiopulm Rehabil Prev. 2009 Jan-Feb;29(1):2-12 - PubMed
  21. J Cardiovasc Pharmacol. 2008 Apr;51(4):365-71 - PubMed
  22. J Cell Biochem. 2003 Sep 1;90(1):23-32 - PubMed
  23. Clin Sci (Lond). 2005 Jun;108(6):493-5 - PubMed
  24. Arterioscler Thromb Vasc Biol. 2008 Nov;28(11):1909-19 - PubMed
  25. Atherosclerosis. 2010 Nov;213(1):33-9 - PubMed
  26. J Am Coll Cardiol. 2002 Jan 16;39(2):257-65 - PubMed
  27. Br J Pharmacol. 2007 Feb;150(4):470-9 - PubMed
  28. Life Sci. 2005 Mar 25;76(19):2257-68 - PubMed
  29. Exp Biol Med (Maywood). 2006 Jun;231(6):772-6 - PubMed
  30. Int J Cardiol. 2008 Mar 28;125(1):136-8 - PubMed
  31. Expert Opin Pharmacother. 2011 Jul;12 (10 ):1463-71 - PubMed
  32. J Am Coll Cardiol. 1995 Nov 1;26(5):1235-41 - PubMed

Publication Types